ArticleAngewandte Chemie (International ed. in English)2026
Redirecting a Native Ene-Reductase Toward Desaturation With Reverse Enantioselectivity.
Article in Angewandte Chemie (International ed. in English), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Redirecting a Native Ene-Reductase Toward Desaturation With Reverse Enantioselectivity.Angewandte Chemie (International ed. in English) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Chiral enones are valuable motifs in synthetic intermediates and bioactive molecules, driving significant interest in biocatalysis. Although recent enzymatic desaturation strategies for substituted cyclohexenones provide efficient and highly enantioselective synthetic routes, none offer complementary stereoselectivity. To address this gap, we introduce a stereocomplementary biocatalytic system based on an old yellow enzyme (OYE), XenA from Pseudomonas putida. Although XenA natively catalyzes the reduction of electron-deficient alkenes and exhibits negligible desaturation activity, protein engineering redirected its catalytic function toward desaturation, ultimately yielding a variant that accommodates a range of cyclohexanones with 85%-99% ee and 32%-98% yield. Remarkably, the optimal variant (XenA_4) possesses 46 mutations and exhibits an 11°C increase in melting temperature over the wild type. Mechanistic studies revealed that the unique dimeric structure of the enzyme is pivotal in controlling stereoselectivity by modulating the substrate-binding orientation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.